氟比洛芬,临床注释-2,变异和临床注释数据

氟比洛芬

临床注释ID

1444842106

药物名称(英)

flurbiprofen

变异单倍型

CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*29

基因

CYP2C9

证据级别

1A

水平覆盖

水平修饰符

Tier 1 VIP

表现型类别(英)

Metabolism/PK

表现型类别

代谢/PK

分数

104.125

PMID计数

3

计数的证据

6

表现型

表现型(英)

最新日期

2021/3/24 0:00:00

URL

https://www.pharmgkb.org/clinicalAnnotation/1444842106

专业人口(英)

专业人口

临床等位基因

id	等位基因	注释文本
1150	*29	The CYP2C929 allele has been assigned as a decreased function allele by CPIC. Patients carrying the CYP2C929 allele in combination with a normal function allele may have decreased metabolism of flurbiprofen as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence flurbiprofen metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and flurbiprofen and does not include evidence about clinical outcomes.
1149	*3	The CYP2C93 allele has been assigned as a no function allele by CPIC. Patients carrying the 3 allele in combination with a normal function allele may have decreased metabolism of flurbiprofen as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence flurbiprofen metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and flurbiprofen and does not include evidence about clinical outcomes.
1148	*2	The CYP2C92 allele has been assigned as a decreased function allele by CPIC. Patients carrying the CYP2C92 allele in combination with a normal function allele may have decreased metabolism of flurbiprofen as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence flurbiprofen metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and flurbiprofen and does not include evidence about clinical outcomes.
1147	*1	The CYP2C91 allele has been assigned as a normal function allele by CPIC. Patients carrying the CYP2C91 allele in combination with another normal function allele may have increased metabolism of flurbiprofen as compared to patients carrying at least one copy of a decreased or no function allele. Other genetic and clinical factors may also influence flurbiprofen metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and flurbiprofen and does not include evidence about clinical outcomes.

临床证据

id	证据的ID	总结
4446	1444828107	CYP2C9 1/1 is associated with increased clearance of flurbiprofen in healthy individuals as compared to CYP2C9 1/3.
4445	1444828093	CYP2C9 1/3 is associated with increased concentrations of flurbiprofen in healthy individuals as compared to CYP2C9 1/1.
4444	1183702553	CYP2C9 1/2 is associated with increased AUC and longer longer flurbiprofen elimination half-life when treated with flurbiprofen in healthy individuals as compared to CYP2C9 1/1.
4443	1183702544	CYP2C9 1/3 is associated with increased AUC, higher half-life and lower flurbiprofen clearance when treated with flurbiprofen in healthy individuals as compared to CYP2C9 1/1.
4442	1451148748	Allele A is associated with decreased catalytic activity of CYP2C9 when assayed with flurbiprofen, naproxen, phenytoin or warfarin as compared to allele C.
4441	PA166191841	Annotation of CPIC Guideline for celecoxib, flurbiprofen, ibuprofen, lornoxicam and CYP2C9

临床病史

id	类型	评论
1644	Update	CA score added as part of scoring system release. LOE assigned following curator review.
1643	Update	added guideline as evidence, updated text
1642	Update	CPIC
1641	Update	Updated phenotype descriptions, added limited evidence tag to *29
1640	Update	Added PMID 32423989 to evidence, added *29 to annotation and updated phenotype descriptions
1639	Update	upgrade to level 1A based on CPIC NSAIDs guideline
1638	Update	AEF 1/24/17 corrected annotation to read reduced function of 2 and 3 compared to *1.
1637	Create

最新招商产品更多>>